74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Hikma Pharmaceuticals PLC
Open
SectorHealthcare
1,910 -0.05
Overview
Share price change
24h
Min
1905
Max
1928
Income | -93M 133M |
|---|---|
Sales | -11M 1.6B |
P/E Sector Avg | 15.451 57.333 |
EPS | 1.27 |
Dividend yield | 3.24 |
Profit margin | 8.537 |
Employees | 9,500 |
EBITDA | -211M 288M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +27.23% upside |
Dividend yield Sector Avg | 3.24% 2.63% |
|---|
Market Cap | -930M 4.2B |
|---|---|
Previous open | 1910.05 |
Previous close | 1910 |
Hikma Pharmaceuticals PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Hikma Pharmaceuticals PLC Forecast
Price Target
By TipRanks
27.23% upside
12 Months Forecast
Average 2,422.5 GBX 27.23%
High 2,650 GBX
Low 2,000 GBX
Based on 7 Wall Street analysts offering 12 month price targets forHikma Pharmaceuticals PLC - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.